Who
Roy C. Hardiman
Chief Business & Strategy Ofcr
Company insider
Files Form 4 as: Chief Business & Strategy Ofcr, Alumis; Chief Business Officer, Principia Biopharma; Director, Pharmacyclics.
In numbers
- Trades disclosed
- 64
- Buys
- 0
- Sells
- 5
- Bought
- $0
- Sold
- $1.4M
- Companies
- 3
- Companies where not an officer
- 1
- First trade
- 9 Dec 2010
- Last trade
- 3 Aug 2026
- Last filed
- 5 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Aug 2026filed 5 Aug 2026 | ALMS AlumisBiotechnology | SEC FORM 4 Sold | $71K2,692 at $26.37 | filing |
| 3 Aug 2026filed 5 Aug 2026 | ALMS AlumisBiotechnology | SEC FORM 4 Sold | $71K2,692 at $26.37 | filing |
| 26 Jan 2026filed 28 Jan 2026 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —190,875 at $0.00 | filing |
| 26 Jan 2026filed 28 Jan 2026 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —190,875 at $0.00 | filing |
| 29 Jul 2025filed 31 Jul 2025 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —111,950 at $0.00 | filing |
| 29 Jul 2025filed 31 Jul 2025 | ALMS AlumisBiotechnology | SEC FORM 4 Code A | —28,000 at $0.00 | filing |
| 18 Feb 2025filed 20 Feb 2025 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code D | —42,780 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —42,780 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code D | —151,871 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —151,871 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code D | —14,973 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,973 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code D | —30,642 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,642 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code D | —206,074 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —206,074 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code D | —53,475 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS Alumisoption or derivative · Biotechnology | SEC FORM 4 Code A | —53,475 at $0.00 | filing |
| 1 Jul 2024filed 1 Jul 2024 | ALMS AlumisBiotechnology | SEC FORM 4 Code D | —175,401 | filing |
News
WAVE Life Sciences (NASDAQ:WVE) and Alumis (NASDAQ:ALMS) Head to Head ComparisonALMS · dailypolitical.com · 18 Oct 2026Alumis Inc.: Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life MeasuresALMS · finanznachrichten.de · 9 Oct 2026
0 headlines in the last 90 days name Roy C. Hardiman; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.